
R_5 is selected from the group consisting of H, an oxygen protecting group, and



, wherein "〰" indicates appoint of attachment;

R_{6a} is optionally substituted C_{1-10} alkyl;

R_{6b} is H, C_{1-10} alkyl, C_{1-10} hydroxyalkyl, allyl, haloalkyl, aryl, heteroalkenyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

R_{8a} and R_{8b} are each independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl;

R_{9a} is selected from the group consisting of H, optionally substituted C_{1-10} alkyl, hydroxyalkyl, optionally substituted C_{1-10} alkylene-$NR_TR_{T'}$, optionally substituted C_{1-10} alkylene-cycloalkyl-$NR_TR_{T'}$, and optionally substituted alkoxyalkyl; wherein R_T and $R_{T'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, and optionally substituted C_{1-10} alkylene-heterocycloalkyl;

~~one of R_{10a} and~~ R_{10b} is selected from the group consisting of H, optionally substituted C_{1-10} alkyl, and optionally substituted C_{1-10} alkoxy~~,~~; and ~~the other of~~

R_{10a} ~~and R_{10b}~~ is selected from the group consisting of $-CO_2H$, $–CO_2$-optionally substituted alkyl, $–CON(R_{z'})(R_{z''})$, optionally substituted C_{1-10} alkylene-R_{101}, optionally substituted C_{2-10} alkenylene-R_{101}, and optionally substituted C_{2-10} alkynylene-R_{101}; wherein:

R_{101} is selected from the group consisting of ~~H,~~ (C_{1-6} alkyl)-S-, (C_{1-6} alkyl)-SO-, (C_{1-6} alkyl)-SO_2-, -OH, optionally substituted -O-(C_{1-6} alkyl), $-NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein:

$R_{z'}$ and $R_{z''}$ are each independently H or optionally substituted alkyl;

R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-$N(R_{y'})(R_{y''})$, wherein $R_{y'}$ and $R_{y''}$ are each independently H or optionally substituted alkyl; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein

each R_y is independently selected from the group consisting of -H and optionally substituted C_{1-10} alkyl; and

R_{11a} and R_{11b} are each independently selected from the group consisting of -H and optionally substituted C_{1-10} alkyl.

~~**[0005b]** In another aspect of the present disclosure, there is provided a compound disclosed herein as depicted in Table A or a pharmaceutically acceptable salt thereof.~~


[0005~~c~~b]In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0005~~d~~c]In another aspect of the present disclosure, there is provided a kit comprising a compound disclosed herein, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition also disclosed herein, and instructions for administering to a subject in need thereof.

[0005~~e~~d]In a further aspect of the present disclosure, there is provided a use of a compound of disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition also disclosed herein, in the manufacture of a medicament for treating an infectious disease in a subject in need thereof.


[0005~~f~~e] In another aspect of the present disclosure, there is provided a compound disclosed herein, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition also disclosed herein, for use in the treatment of an infectious disease in a subject in need thereof.

~~**[0005g]** In a further aspect of the present disclosure, there is provided a compound of formula N-a:~~



N-a


or a salt thereof, wherein R_{4a}, R_{4b}, R_5, R_{6a}, R_{6b}, R_{8a}, R_{8b}, R_{10a}, R_{10b}, R_{11a}, and R_{11b} are as disclosed herein;

G^4 is 

; each instance of R^{15} is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R^{15} groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and


each instance of R^{16a} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and PG is a protecting group.

[0005h] In another aspect of the present disclosure, there is provided a process of preparing a compound of formula I as disclosed herein, comprising cyclization of a compound of formula N-a:




N-a I.

[0005i] In a further aspect of the present disclosure, there is provided a process of preparing a compound of formula I as disclosed herein; comprising cyclizing a compound of formula N-a wherein R_{9a} is H to provide a compound of formula P wherein R_{9a} is H; followed by reductive amination and deprotection to provide a compound of formula I wherein R_{9a} is C_{1-10} alkyl, hydroxyalkyl, or alkoxyalkyl












[0005j] ~~In another aspect of the present disclosure, there is provided a process of preparing a compound of formula I as disclosed herein, comprising alkylating a compound of formula A with R_{2b}-LG in the presence of base, wherein LG is a leaving group, to provide after deprotection a compound of formula I~~













~~A~~ ~~I.~~






[0005f] In a further aspect of the present disclosure, there is provided a compound which is selected from:






Compound #	Structure
2	
3	
4	
5	
6	






Compound #	Structure
7	
8	
9	
10	





Compound #	Structure
11	
12	
13	
15	
16	





Compound #	Structure
17	
18	
19	
20	
21	

Compound #	Structure
168	
193	
200	
201	
202	

Compound #	Structure
203	
204	
212	
221	
223	





Compound #	Structure
224	
225	
228	
229	
231	






Compound #	Structure
233	
234	
235	
236	





Compound #	Structure
237	
238	
239	 and
240	 ;





or a pharmaceutically acceptable salt thereof.





[0005g] In another aspect of the present disclosure, there is provided a compound which is selected from:





Compound #	Structure
1	
22	
23	
24	






Compound #	Structure
25	
26	
27	
28	
29	






Compound #	Structure
35	
36	
37	
38	






Compound #	Structure
39	
40	
41	
42	





Compound #	Structure
44	
45	
46	
47	






Compound #	Structure
48	
49	
50	
51	






Compound #	Structure
52	
53	
54	
55	
56	






Compound #	Structure
57	
58	
59	
60	
61	






Compound #	Structure
62	
63	
64	
65	
66	






Compound #	Structure
67	
68	
69	
70	






Compound #	Structure
71	
72	
73	
74	
75	






Compound #	Structure
76	
77	
78	
79	
80	






Compound #	Structure
81	
82	
83	
84	
85	






Compound #	Structure
86	
87	
88	
89	
90	






Compound #	Structure
91	
92	
93	
94	
95	






Compound #	Structure
96	
97	
98	
99	
101	






Compound #	Structure
102	
103	
104	
105	
106	






Compound #	Structure
107	
108	
109	
110	
111	






Compound #	Structure
112	
113	
114	
115	
116	






Compound #	Structure
117	
118	
119	
121	
122	






Compound #	Structure
123	
124	
125	
127	
128	






Compound #	Structure
129	
130	
131	
132	
133	





Compound #	Structure
134	
135	
136	
137	
138	





Compound #	Structure
139	
140	
142	
144	
146	





Compound #	Structure
147	
148	
149	
150	
151	






Compound #	Structure
153	
154	
155	
156	
157	




Compound #	Structure
158	
159	
160	
161	
162	




Compound #	Structure
163	
164	
165	
166	






Compound #	Structure
169	
170	
171	
172	







Compound #	Structure
173	
174	
175	
176	



Compound #	Structure
178	
180	
181	
189	
190	

Compound #	Structure
192	
194	
195	

Compound #	Structure
196	
197	
198	



Compound #	Structure
199	
205	
208	
209	
216	






Compound #	Structure
217	
218	
219	
220	
227	
230	




Compound #	Structure
232	 and
233	 ;

or a pharmaceutically acceptable salt thereof.

[0005h] In a further aspect of the present disclosure, there is provided a compound which is selected from:

Compound #	Structure
112	
120	


Compound #	Structure
126	
141	
143	
145	
152	

Compound #	Structure
177	
182	 and
226	 ;

or a pharmaceutically acceptable salt thereof.

[0006] Disclosed herein are compounds that are novel, synthetically accessible 13-membered macrolides. The compounds are novel antibiotics with unexpectedly potent antimicrobial activity.

[0007] In one example, the present disclosure provides compounds of Formula (**I**):




or a pharmaceutically acceptable salt thereof, wherein:

one of R_{2a} and R_{2b} is selected from the group consisting of H, halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and

the other of R_{2a} and R_{2b} is selected from the group consisting of halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, substituted amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

CLAIMS

1. A compound of Formula I:



I


or a pharmaceutically acceptable salt thereof, wherein:

one of R_{2a} and R_{2b} is selected from the group consisting of H, halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and

the other of R_{2a} and R_{2b} is selected from the group consisting of halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, substituted amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

each of R_{4a} and R_{4b} is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl;

R_5 is selected from the group consisting of H, an oxygen protecting group, and



, wherein "〰" indicates appoint of attachment;

R_{6a} is optionally substituted C_{1-10} alkyl;

R_{6b} is H, C_{1-10} alkyl, C_{1-10} hydroxyalkyl, allyl, haloalkyl, aryl, heteroalkenyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

R_{8a} and R_{8b} are each independently selected from the group consisting of H and optionally substituted $C_{1\text{-}10}$ alkyl;

R_{9a} is selected from the group consisting of H, optionally substituted $C_{1\text{-}10}$ alkyl, hydroxyalkyl, optionally substituted $C_{1\text{-}10}$ alkylene-$NR_TR_{T'}$, optionally substituted $C_{1\text{-}10}$ alkylene-cycloalkyl-$NR_TR_{T'}$, and optionally substituted alkoxyalkyl; wherein R_T and $R_{T'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, and optionally substituted $C_{1\text{-}10}$ alkylene-heterocycloalkyl;

~~one of R_{10a} and~~ R_{10b} is selected from the group consisting of H, optionally substituted $C_{1\text{-}10}$ alkyl, and optionally substituted $C_{1\text{-}10}$ alkoxy~~,~~; and ~~the other of~~

R_{10a} ~~and R_{10b}~~ is selected from the group consisting of -CO_2H, –CO_2-optionally substituted alkyl, –CON($R_{z'}$)($R_{z''}$), optionally substituted $C_{1\text{-}10}$ alkylene-R_{101}, optionally substituted $C_{2\text{-}10}$ alkenylene-R_{101}, and optionally substituted $C_{2\text{-}10}$ alkynylene-R_{101}; wherein:

R_{101} is selected from the group consisting of ~~H,~~ ($C_{1\text{-}6}$ alkyl)-S-, ($C_{1\text{-}6}$ alkyl)-SO-, ($C_{1\text{-}6}$ alkyl)-SO_2-, -OH, optionally substituted -O-($C_{1\text{-}6}$ alkyl), -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein:

$R_{z'}$ and $R_{z''}$ are each independently H or optionally substituted alkyl;


R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-N($R_{y'}$)($R_{y''}$), wherein $R_{y'}$ and $R_{y''}$ are each independently H or optionally substituted alkyl; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein

each R_y is independently selected from the group consisting of -H and optionally substituted $C_{1\text{-}10}$ alkyl; and

R_{11a} and R_{11b} are each independently selected from the group consisting of -H and optionally substituted $C_{1\text{-}10}$ alkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula IG:



IG.


3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R_{9a} is -H or C_{1-4} alkyl.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R_{11a} and R_{11b} are each methyl.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein one of R_{2a} and R_{2b} is optionally substituted C_{1-10} alkyl.


6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein one of R_{2a} and R_{2b} is methyl and the other is halo.

7. The compound of claim 3, or a pharmaceutically acceptable salt thereof, which is a compound of formula IH:




IH.


8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, which is a compound of formula IIA, IIB, IIC, or IID:




IIA;



IIB;



IIC;



IID;

~~wherein one of R_{10a} and~~ R_{10b} is selected from the group consisting of H and optionally substituted $C_{1\text{-}10}$ alkyl; and

~~the other of~~ R_{10a} ~~and R_{10b}~~ is selected from the group consisting of -CO_2H, –CO_2-optionally substituted alkyl, –$CON(R_{z'})(R_{z''})$, and optionally substituted C_{1}-$_{10}$ alkylene-R_{101}, C_{2}-$_{10}$ alkenylene-R_{101}, and C_{2}-$_{10}$ alkynylene-R_{101}; wherein

R_{101} is selected from the group consisting of ~~H,~~ ($C_{1\text{-}6}$ alkyl)-S-, ($C_{1\text{-}6}$ alkyl)-SO-, ($C_{1\text{-}6}$ alkyl)-SO_2-, -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_x and $R_{x'}$ are each independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-$N(R_{y'})(R_{y''})$; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein:

each R_y is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R_{9a} is –H, methyl, ethyl, propyl, isopropyl, butyl, or isobutyl.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is selected from the group consisting of optionally substituted C_{1-10} alkylene-R_{101}, C_{2-10} alkenylene-R_{101}, and C_{2-10} alkynylene-R_{101}; wherein:

R_{101} is selected from the group consisting of ~~H,~~ -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R_{101} is selected from the group consisting H, -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_x and $R_{x'}$ are each independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-$N(R_{y'})(R_{y''})$; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein:

each R_y is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl; and

R_{10b} ~~a~~ is selected ~~selected~~ from the group consisting of H and optionally substituted C_{1-10} alkyl~~, -CO_2H, and -CO_2-alkyl~~.































11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:






R_{10a} is -C_1-C_{10} alkylene-R_{101a};

R_{101a} is selected from the group consisting of ~~H,~~ (C_{1-6} alkyl)-S-, (C_{1-6} alkyl)-SO-, (C_{1-6} alkyl)-SO_2-, -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally

substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-N($R_{y'}$)($R_{y''}$); or R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein each R_y is independently selected from the group consisting of -H and optionally substituted $C_{1\text{-}10}$ alkyl.


12. The compound of claim 11, or a pharmaceutically acceptable salt thereof,


wherein R_{10a} is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , .





, and

;

wherein


$NR_xR_{x'}$ is selected from the group consisting of -N(Me)(Et), -N(Me)$_2$, -N(Me)(t-Bu), -N(Me)(iPr), -NH(Me), -NH(iPr), -N(Et)$_2$, -N(Me)(cyclopropyl), -NH(cyclopropyl), -N(Me)(cyclobutyl), -NH(cyclobutyl), -N(Me)(cyclopentyl), -NH(cyclopentyl), -N(Me)(cyclohexyl), and -NH(cyclohexyl);

$MeSCH_2CH_2$-, $MeSOCH_2CH_2$-, $MeSO_2CH_2CH_2$-, , and

, and wherein "" indicates a point of attachment.


13. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted R_{101a2}-CH_2-, R_{101a2}-CH(OH)-, R_{101a2}-CH(OMe)-,

, or R_{101a2}-C(=O)-, wherein "" indicates a point of attachment; and

R_{101a2} is selected from the group consisting of ~~-H,~~ -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-N($R_{y'}$)($R_{y''}$); or R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and whereineach R_y is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl.
















14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein:















R_{101a2}-CH_2- is -CH_2NHMe, -CH_2N(Me)$_2$, -CH_2N(Me)(cyclopropyl), -CH_2NH(oxetanyl), -CH_2NHCH$_2$(cyclopropyl), ~~and~~ or , wherein " ~~~ " indicates a point of attachment.










15. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is R_{101a2}-CH_2-; and

R_{101a2} is selected from the group consisting of optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.


16. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is an optionally substituted R_{101a2}-CH_2-, R_{101a2}-CH(OH)-, R_{101a2}-CH(OMe)-, , or R_{101a2}-C(=O)-, wherein " ~~~ " indicates a point of attachment; and R_{101a2} is an optionally substituted piperidinyl selected from the group consisting of , , , , , , , , , , , , , .









































, and , wherein "" indicates a point of attachment.

17. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted R_{101a2}-CH_2-, R_{101a2}-CH(OH)-, R_{101a2}-CH(OMe)-, , or R_{101a2}-C(=O)-, wherein "" indicates a point of attachment; and

R_{101a2} is an optionally substituted  selected from the group consisting of






, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, and 
,

wherein "〰" indicates a point of attachment.

18. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein:


R_{10a} is an optionally substituted R_{101a3}-CH_2-, R_{101a3}-CH(OH)-, R_{101a3}-CH(OMe)-,


, or R_{101a3}-C(=O)-, wherein "〰" indicates a point of attachment; and

R_{101a3} is an optionally substituted heteroaryl.

19. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein:



R_{10a} is an optionally substituted R_{101a4}-CH_2-, R_{101a4}-CH(OH)-, R_{101a4}-CH(OMe)-,


, or R_{101a4}-C(=O)-, wherein "〰" indicates a point of attachment; and

R_{101a4} is an optionally substituted azetidinyl.


20. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted azetidinyl-CH_2- selected from the group consisting of


and 
, wherein "〰" indicates a point of attachment.

21. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted R_{101a5}-CH_2-, R_{101a5}-CH(OH)-, R_{101a5}-CH(OMe)-,




, or R_{101a5}-C(=O)-, wherein "〰" indicates a point of attachment; and


R_{101a5} is an optionally substituted cyclobutyl.

22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein:


R_{101}-CH_2- is an optionally substituted cyclobutyl selected from the group consisting of




,



,



, and



,

wherein "〰" indicates a point of attachment.

23. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:


R_{10a} is an optionally substituted $C_{2\text{-}10}$ alkenylene-R_{101};


R_{101} is selected from the group consisting of ~~-H,~~ -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein

R_x and $R_{x'}$ are each independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-$N(R_{y'})(R_{y''})$; or



R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein






each R_y is independently selected from the group consisting of -H and optionally substituted $C_{1\text{-}10}$ alkyl.






24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is an optionally substituted C_{2-5} alkenylene-R_{101} selected from the group consisting of , and .






25. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is an optionally substituted alkenylene-R_{101} which is , wherein A is an optionally substituted cycloalkyl or heterocycloalkyl and R_{101e} is selected from the group consisting of -H, alkyl, and -$NR_xR_{x'}$, wherein R_x and $R_{x'}$ are each independently selected from the group consisting of -H and optionally substituted alkyl, and wherein "〰" indicates a point of attachment.






26. A compound which is selected from: ~~of claim 1 as depicted in Table A~~






Compound #	Structure
2	
3	






Compound #	Structure
4	
5	
6	
7	
8	





Compound #	Structure
9	
10	
11	
12	
13	





Compound #	Structure
15	
16	
17	
18	
19	



Compound #	Structure
20	
21	
168	
193	
200	

Compound #	Structure
201	
202	
203	
204	
212	

Compound #	Structure
221	
223	
224	
225	
228	



Compound #	Structure
229	
231	
233	
234	






Compound #	Structure
235	
236	
237	
238	





Compound #	Structure
239	 and
240	 ;





or a pharmaceutically acceptable salt thereof.





27. A compound which is selected from:





Compound #	Structure
1	
22	






Compound #	Structure
23	
24	
25	
26	
27	






Compound #	Structure
28	
29	
35	
36	






Compound #	Structure
37	
38	
39	
40	





Compound #	Structure
41	
42	
44	
45	





Compound #	Structure
46	
47	
48	
49	






Compound #	Structure
50	
51	
52	
53	
54	






Compound #	Structure
55	
56	
57	
58	
59	






Compound #	Structure
60	
61	
62	
63	
64	







Compound #	Structure
65	
66	
67	
68	






Compound #	Structure
69	
70	
71	
72	






Compound #	Structure
73	
74	
75	
76	
77	






Compound #	Structure
78	
79	
80	
81	
82	






Compound #	Structure
83	
84	
85	
86	
87	






Compound #	Structure
88	
89	
90	
91	
92	
93	







Compound #	Structure
94	
95	
96	
97	
98	






Compound #	Structure
99	
101	
102	
103	
104	






Compound #	Structure
105	
106	
107	
108	
109	






Compound #	Structure
110	
111	
112	
113	
114	






Compound #	Structure
115	
116	
117	
118	
119	






Compound #	Structure
121	
122	
123	
124	
125	
127	






Compound #	Structure
128	
129	
130	
131	
132	





Compound #	Structure
133	
134	
135	
136	
137	





Compound #	Structure
138	
139	
140	
142	
144	





Compound #	Structure
146	
147	
148	
149	
150	






Compound #	Structure
151	
153	
154	
155	
156	




Compound #	Structure
157	
158	
159	
160	
161	




Compound #	Structure
162	
163	
164	
165	





Compound #	Structure
166	
169	
170	
171	







Compound #	Structure
172	
173	
174	
175	





Compound #	Structure
176	
178	
180	
181	
189	

Compound #	Structure
190	
192	
194	

Compound #	Structure
195	
196	
197	






Compound #	Structure
198	
199	
205	
208	






Compound #	Structure
209	
216	
217	
218	
219	
220	

Compound #	Structure
227	
230	
232	 and
233	 ;

or a pharmaceutically acceptable salt thereof.

28. A compound which is selected from:

Compound #	Structure
112	
120	
126	
141	
143	

Compound #	Structure
145	
152	
177	
182	 and
226	 ;

or a pharmaceutically acceptable salt thereof.

297. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

3028. A kit comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 297, and instructions for administering to a subject in need thereof.


3129. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 297, in the manufacture of a medicament for treating an infectious disease in a subject in need thereof.

3032. The use of claim 3129, wherein the infectious disease is a gram-negative or gram-positive bacterial infection or a parasitic infection.


3133. A compound of claim 1, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 297, for use in the treatment of an infectious disease in a subject in need thereof.

3432. The compound or pharmaceutical composition for use of claim 331, wherein the infectious disease is a gram-positive or gram-negative bacterial infection or a parasitic infection.

~~33. A compound of formula N-a:~~




~~or a salt thereof, wherein R_{4a}, R_{4b}, R_5, R_{6a}, R_{6b}, R_{8a}, R_{8b}, R_{10a}, R_{10b}, R_{11a}, and R_{11b} are as defined in claim 1;~~

~~G^4 is~~  ~~;~~

~~each instance of R^{15} is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R^{15} groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and~~


~~each instance of R^{16a} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and PG is a protecting group.~~


~~34. A process of preparing a compound of formula I of claim 1, comprising cyclization of a compound of formula N-a:~~



~~N-a I.~~


~~35. The process of claim 34, further comprising the step of preparing a compound of formula N-a, by combining N-1 with N-2 under reductive amination conditions:~~






~~wherein R_s is , PG is a protecting group, and "〰" indicates a point of attachment.~~

~~36. A process of preparing a compound of formula I as defined in claim 1; comprising cyclizing a compound of formula N-a wherein R_{9a} is H to provide a compound of formula P wherein R_{9a} is H; followed by reductive amination and deprotection to provide a compound of formula I wherein R_{9a} is C_{1-10} alkyl, hydroxyalkyl, or alkoxyalkyl~~



37. ~~A process of preparing a compound of formula I as defined in claim 1, comprising alkylating a compound of formula A with R_{2b}-LG in the presence of base, wherein LG is a leaving group, to provide after deprotection a compound of formula I~~



~~A~~ ~~I.~~